Omni Bio Pharmaceutical Appoints Jack Riccardi As Chief Financial Officer
8/14/2014 1:32:10 PM
Fort Collins, CO, August 14, 2014 – Omni Bio Pharmaceutical, Inc. (OTCPK: OMBP)
(“Omni Bio”), an emerging biopharmaceutical company focused on revolutionizing the
treatment of immune-mediated inflammatory diseases, announced today the appointment
of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of
financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and
served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi’s
appointment will become effective on September 1, 2014.
Bruce Schneider, Ph.D., Chief Executive Officer of Omni Bio, commented, “As Omni
Bio continues to evolve its business, we are very pleased to add such a seasoned financial
leader to our team. Jack has a proven ability in leading financially driven business
development and operating activities strategically and efficiently, and also has significant
experience in dealing with the financial markets. His maturity and experience will be of
great benefit to Omni Bio as we continue development of our first-in-class recombinant
Fc-AAT technology platform.”
Mr. Riccardi stated, “I feel Omni Bio is uniquely positioned to capture a multitude of
emerging clinical opportunities with its Fc-AAT platform. I am thrilled to join the
company at this exciting product development stage, where my expertise in managing
business and commercial operations will help support advancement of this pioneering
Prior to his role at Green Street Ventures, Mr. Riccardi served as Chief Financial Officer,
Treasurer and Secretary of ADial Pharmaceuticals, where he oversaw the
commercialization effort, drug market studies, and advanced valuation analyses for
several late stage pharmacotherapies. He also served as Chief Financial Officer of
Modern Visuals, a software start-up venture spun off from Siemens Technology Group,
where he successfully prepared the company for its eventual sale to a strategic buyer. Mr.
Riccardi spent eight years at General Motors (GM), last serving as Director, Strategic
Planning. While at GM, Jack initiated content acquisition and strategic alliance efforts
expanding GM’s OnStar brand into new household markets, established the company’s
corporate technology venture fund for direct investment into promising technologies, and
founded the company’s Business Development Forum.
Mr. Riccardi holds a BS in Accounting from Pennsylvania State University, an MBA
from the Wharton School of Business at the University of Pennsylvania, and an MS in
Operations Science from London School of Economics and Political Science.
About Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc. (“Omni Bio”) is an emerging biopharmaceutical company
focused on revolutionizing the treatment of immune-mediated inflammatory disease. The
Company’s technology platform, Fc-AAT, is a recombinant version of plasma-derived
alpha-1 antitrypsin (p-AAT), a naturally occurring human protein that is currently
commercialized as an intravenous supplementation therapy for AAT-deficient
individuals. Omni Bio seeks to capitalize on emerging scientific evidence of AAT's
fundamental role in mediating multiple anti-inflammatory and tissue protective pathways
by developing first-in-class therapeutics to address a broad array of new clinical
Omni Bio’s recombinant Fc-AAT can offer several potential advantages over current p-
AAT products, including superior potency, longer half-life, improved safety and easy-toadminister
subcutaneous dosing, as well as significantly enhanced manufacturing
scalability. Omni Bio intends to exploit Fc-AAT’s enhanced product potential to address
multiple, high-value immune-mediated inflammatory disease indications, such as Type 1
diabetes, graft versus host disease and treatment refractory gout. The Company holds
broad intellectual property covering both recombinant and plasma-derived AAT for these
and other indications.
For more information, please visit http://www.omnibiopharma.com.
This press release contains forward-looking statements that reflect the Company’s current
expectations as of the date of this press release, and involve certain risks and
uncertainties that could cause actual results to differ materially from those anticipated in
these forward- looking statements. Factors that could cause future results to materially
differ from forward-looking statements include the risks described in Omni Bio
Pharmaceutical, Inc.'s Form 10-K for the fiscal year ended March 31, 2014 and other
reports filed with the Securities and Exchange Commission. The Company undertakes no
obligation to publicly update or revise any forward-looking statements. The Company's
further development is highly dependent on raising capital to support its activities, future
medical and research developments and market acceptance, and other risks that are
outside of the Company's control.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
firstname.lastname@example.org; (212) 375-2664
Amy Wheeler (Media)
email@example.com; (646) 362-5750
Omni Bio Pharmaceuticals, Inc.
firstname.lastname@example.org; (720) 488-4708
Help employers find you! Check out all the jobs and post your resume.
comments powered by